AB Vista is an animal nutrition technology company offering pioneering products and technical services to the global animal feed industry. With its headquarters in the UK, the company employs over 190 staff globally and has support offices worldwide.
Assess feed quality to make smarter nutritional and commercial decisions.
Measure enzyme activity to ensure consistent quality control.
Optimise the feed manufacturing process.
Click on the logos to find out more about our events.
AB Vista is committed to facilitating discussions around animal nutrition technology and gathering experts to provide independent opinions. Our ultimate aim is to research and apply science that brings real value commercially to the animal production industry.
Stay ahead with the latest news, ideas and events.
AB Vista is committed to bringing new ways of thinking to the global feed industry. Our work attracts enquiring minds who see things differently and embrace the changing landscape – offering our clients an interested, innovative and up-to-date partner.
Monday, January 25, 2016
Superdosing – where are the benefits coming from? Part one: complete phytate destruction
READ MORE ▶
Thursday, January 7, 2016
AB Vista is launching a technical video series at this year’s International Production and Processing Expo (IPPE) in January, aimed at sharing information on various key areas of development within animal nutrition technology for 2016.
Wednesday, December 2, 2015
AB Vista would like to announce that Dr. Robert Van Wyhe has joined the North American technical team.
Wednesday, November 4, 2015
AB Vista has announced sales growth of more than 20% for the financial year ended 13 September 2015.
Monday, November 2, 2015
AB Vista has announced a new partnership with Milan-based distribution company Garzanti Specialties S.p.A, to supply its current enzyme portfolio to the Italian market, including the intrinsically thermostable xylanase Econase XT and modified E.coli phytase, Quantum Blue.
A regular summary of our key stories sent straight to your inbox.
Subscribe
Receive a regular summary of our key stories sent straight to your inbox.
A regular summary of our key stories sent straight to your inbox